HDL particle functionality as a primary pharmacological target for HDL-based therapies

Biochemical Pharmacology

Volumn 85, Issue 11, 2013, Pages 1575-1578

  Kypreos, Kyriakos E ^a   Gkizas, Spyridon ^a   Rallidis, Loukianos S ^b   Karagiannides, Iordanis ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Coronary disease; HDL quality; HDL based therapies; Pharmacology

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TORCETRAPIB;

ATHEROSCLEROSIS; HEART PROTECTION; HUMAN; LIPID COMPOSITION; NONHUMAN; PLASMA; PRIORITY JOURNAL; REVIEW;

EID: 84877609722     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.03.004     Document Type: Note

References (45)

1. E.M. Tsompanidi, M.S. Brinkmeier, E.H. Fotiadou, S.M. Giakoumi, and K.E. Kypreos HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis Atherosclerosis 208 2009 3 9
2. L.A. Soloff Intermediate lipoproteins, atherosclerosis, and Gofman Circulation 97 1998 708
3. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 1977 707 714
4. J.P. Despres, I. Lemieux, G.R. Dagenais, B. Cantin, and B. Lamarche HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study Atherosclerosis 153 2000 263 272
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
6. J.C. Fruchart, F. Sacks, M.P. Hermans, G. Assmann, W.V. Brown, and R. Ceska The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 2008 1K 34K
7. U.K. Sampson, S. Fazio, and M.F. Linton Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges Curr Atheroscler Rep 14 2012 1 10
8. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, and R. Belder Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
9. T.R. Pedersen, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, and I. Holme High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial J Am Med Assoc 294 2005 2437 2445
10. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, and J.C. Fruchart Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
11. Z.J. Zheng, J.B. Croft, W.H. Giles, and G.A. Mensah Sudden cardiac death in the United States, 1989 to 1998 Circulation 104 2001 2158 2163
12. K.Y. Chyu, A. Peter, and P.K. Shah Progress in HDL-based therapies for atherosclerosis Curr Atheroscler Rep 13 2011 405 412
13. D.J. Gordon, J.L. Probstfield, R.J. Garrison, J.D. Neaton, W.P. Castelli, and J.D. Knoke High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
14. H. Bays, and E.A. Stein Pharmacotherapy for dyslipidaemia - current therapies and future agents Expert Opin Pharmacother 4 2003 1901 1938
15. M.E. Brousseau, E.J. Schaefer, M.L. Wolfe, L.T. Bloedon, A.G. Digenio, and R.W. Clark Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515
16. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, and M. Komajda Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
17. A.R. Tall, L. Yvan-Charvet, and N. Wang The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 27 2007 257 260
18. M.J. Forrest, D. Bloomfield, R.J. Briscoe, P.N. Brown, A.M. Cumiskey, and J. Ehrhart Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br J Pharmacol 154 2008 1465 1473
19. E.A. Stein, E.M. Roth, J.M. Rhyne, T. Burgess, D. Kallend, and J.G. Robinson Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial Eur Heart J 31 2010 480 488
20. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, and A.M. Gotto Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
21. S.J. Nicholls, H.B. Brewer, J.J. Kastelein, K.A. Krueger, M.D. Wang, and M. Shao Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial J Am Med Assoc 306 2011 2099 2109
22. G. Cao, T.P. Beyer, Y. Zhang, R.J. Schmidt, Y.Q. Chen, and S.L. Cockerham Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure J Lipid Res 52 2011 2169 2176
23. Z.A. Fayad, V. Mani, M. Woodward, D. Kallend, M. Abt, and T. Burgess Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial Lancet 378 2011 1547 1559
24. T.F. Luscher, S. Taddei, J.C. Kaski, J.W. Jukema, D. Kallend, and T. Munzel Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial Eur Heart J 33 2012 857 865
25. G.G. Schwartz, A.G. Olsson, M. Abt, C.M. Ballantyne, P.J. Barter, and J. Brumm Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
26. J.M. Timmins, J.Y. Lee, E. Boudyguina, K.D. Kluckman, L.R. Brunham, and A. Mulya Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I J Clin Invest 115 2005 1333 1342
27. L.R. Brunham, J.K. Kruit, J. Iqbal, C. Fievet, J.M. Timmins, and T.D. Pape Intestinal ABCA1 directly contributes to HDL biogenesis in vivo J Clin Invest 116 2006 1052 1062
28. A.K. Soutar, C.W. Garner, H.N. Baker, J.T. Sparrow, R.L. Jackson, and A.M. Gotto Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase Biochemistry 14 1975 3057 3064
29. Y.L. Marcel, P.K. Weech, T.D. Nguyen, R.W. Milne, and W.J. McConathy Apolipoproteins as the basis for heterogeneity in high-density lipoprotein2 and high-density lipoprotein3. Studies by isoelectric focusing on agarose films Eur J Biochem 143 1984 467 476
30. B.F. Asztalos, P.S. Roheim, R.L. Milani, M. Lefevre, J.R. McNamara, and K.V. Horvath Distribution of apoA-I-containing HDL subpopulations in patients with coronary heart disease Arterioscler Thromb Vasc Biol 20 2000 2670 2676
31. K.E. Kypreos, and V.I. Zannis Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT Biochem J 403 2007 359 367
32. K.E. Kypreos ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia Biochemistry 47 2008 10491 10502
33. R. Huang, R.A. Silva, W.G. Jerome, A. Kontush, M.J. Chapman, and L.K. Curtiss Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma Nat Struct Mol Biol 18 2011 416 422
34. J.P. Segrest, S.C. Harvey, and V. Zannis Detailed molecular model of apolipoprotein A-I on the surface of high-density lipoproteins and its functional implications Trends Cardiovasc Med 10 2000 246 252
35. E.A. Karavia, D.J. Papachristou, K. Liopeta, I.E. Triantafyllidou, O. Dimitrakopoulos, and K.E. Kypreos Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice Mol Med 18 2012 901 912 10.2119/molmed.2012.00113
36. E.A. Karavia, D.J. Papachristou, I. Kotsikogianni, I.-E. Triantafyllidou, and K.E. Kypreos Lecithin: cholesterol acyltransferase modulates diet-induced hepatic deposition of triglycerides in mice J Nutr Biochem 24 3 2013 567 577 10.1016/j.jnutbio.2012.02.007 Epub 2012 Jul 20
37. I.E. Triantaphyllidou, E. Kalyvioti, E. Karavia, I. Lilis, K.E. Kypreos, and D.J. Papachristou Perturbations in the HDL metabolic pathway predispose to the development of osteoarthritis in mice following long-term exposure to western-type diet Osteoarthritis Cartilage 21 2 2013 322 330 10.1016/j.joca.2012.11.003 Epub 2012 Nov 11
38. W.J. Carman, M. Sowers, V.M. Hawthorne, and L.A. Weissfeld Obesity as a risk factor for osteoarthritis of the hand and wrist: a prospective study Am J Epidemiol 139 1994 119 129
39. S. Dahaghin, S.M. Bierma-Zeinstra, B.W. Koes, J.M. Hazes, and H.A. Pols Do metabolic factors add to the effect of overweight on hand osteoarthritis? The Rotterdam Study Ann Rheum Dis 66 2007 916 920
40. S. Dahaghin, S.M. Bierma-Zeinstra, M. Reijman, H.A. Pols, J.M. Hazes, and B.W. Koes Does hand osteoarthritis predict future hip or knee osteoarthritis? Arthritis Rheum 52 2005 3520 3527
41. W. Khovidhunkit, M.S. Kim, R.A. Memon, J.K. Shigenaga, A.H. Moser, and K.R. Feingold Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host J Lipid Res 45 2004 1169 1196
42. F.C. McGillicuddy, M.M. de la Llera, C.C. Hinkle, M.R. Joshi, E.H. Chiquoine, and J.T. Billheimer Inflammation impairs reverse cholesterol transport in vivo Circulation 119 2009 1135 1145
43. D.M. Levine, T.S. Parker, T.M. Donnelly, A. Walsh, and A.L. Rubin In vivo protection against endotoxin by plasma high density lipoprotein Proc Natl Acad Sci U S A 90 1993 12040 12044
44. D. Pajkrt, J.E. Doran, F. Koster, P.G. Lerch, B. Arnet, and T. van der Poll Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia J Exp Med 184 1996 1601 1608
45. A. Wu, C.J. Hinds, and C. Thiemermann High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications Shock 21 2004 210 221